Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

NCT02301936 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: LDV/SOF

Sponsor

Gilead Sciences